Small Pharma To Present At Canaccord Genuity's Annual Growth Conference

Progress in the development of DMT-assisted therapy for the treatment of depression

LONDON, Aug. 9, 2021 /PRNewswire/ -- Small Pharma Inc. (TSXV: DMT) (the "Company" or "Small Pharma"), a neuropharmaceutical company focused on psychedelic-assisted therapies, today announced that Peter Rands, Chief Executive Officer, and Dr. Carol Routledge, Chief Medical and Scientific Officer, will present at Canaccord Genuity's 41^st Annual Growth Conference on Tuesday, August 10, 2021.

The Small Pharma presentation will be scheduled to begin at 8:30 a.m. Eastern Time. A link to the live webcast presentation and a replay will be made available on the "Events" section of the Company's investor relations page: https://www.smallpharma.co.uk/investors.

Small Pharma's lead candidate SPL026 is currently being trialed in a Phase I/IIa randomized-controlled clinical trial for Major Depressive Disorder in the UK. Topline data readout of the Phase IIa proof of concept data is anticipated in H1 2022.

About Small Pharma

Small Pharma is a neuropharmaceutical company specialised in IP-led development of novel treatments for mental health conditions, with a focus on depression. Small Pharma initiated a clinical program into N,N-dimethyltryptamine ("DMT") assisted therapy in February 2021. This program includes a Phase I/IIa trial on the Company's lead candidate alongside development of a robust pipeline of proprietary preclinical assets.

For further information contact: 

Small Pharma
Peter Rands
Chief Executive Officer
Email: ir@smallpharma.co.uk
Tel: +44 (0)2071 129118

Investor Relations Contact
Eric Ribner
LifeSci Advisors
Email: eric@lifesciadvisors.com

Cautionary Note

Small Pharma makes no medical, treatment or health benefit claims about its proposed products. The Medicines and Healthcare products Regulatory Agency ("MHRA") or other similar regulatory authorities have not evaluated claims regarding DMT-assisted therapies and other next generation psychoactive compounds. The efficacy of such therapies have not been confirmed by MHRA-approved research. There is no assurance that such DMT-assisted therapies and other psychoactive compounds can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. Any references to quality, consistency, efficacy and safety of potential therapies do not imply that Small Pharma verified such in clinical trials or that Small Pharma will complete such trials. If Small Pharma cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Small Pharma's performance and operations. 

The TSX Venture Exchange (the "TSXV") has neither approved nor disapproved the contents of this news release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.